GSK

1,457

+0.24%↑

HLN.UK

395.5

+0.94%↑

INDV

719.5

-2.04%↓

GSK

1,457

+0.24%↑

HLN.UK

395.5

+0.94%↑

INDV

719.5

-2.04%↓

GSK

1,457

+0.24%↑

HLN.UK

395.5

+0.94%↑

INDV

719.5

-2.04%↓

GSK

1,457

+0.24%↑

HLN.UK

395.5

+0.94%↑

INDV

719.5

-2.04%↓

GSK

1,457

+0.24%↑

HLN.UK

395.5

+0.94%↑

INDV

719.5

-2.04%↓

Search

AstraZeneca PLC

Open

BrancheGesundheitswesen

11,248 -1.18

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11106

Max

11550

Schlüsselkennzahlen

By Trading Economics

Einkommen

237M

1.7B

Verkäufe

1.3B

15B

KGV

Branchendurchschnitt

32.661

63.778

EPS

2.09

Dividendenrendite

2.18

Gewinnspanne

11.188

Angestellte

94,300

EBITDA

-235M

4.4B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+22.93% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.18%

2.39%

Nächstes Ergebnis

29. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.8B

179B

Vorheriger Eröffnungskurs

11249.18

Vorheriger Schlusskurs

11248

Nachrichtenstimmung

By Acuity

47%

53%

156 / 386 Ranking in Healthcare

AstraZeneca PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. März 2025, 03:15 UTC

Wichtige Markttreiber

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17. März 2025, 07:42 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

3. Apr. 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3. Apr. 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3. Apr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31. März 2025, 09:31 UTC

Heiße Aktien

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

17. März 2025, 14:43 UTC

Market Talk

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17. März 2025, 13:55 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

17. März 2025, 07:04 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

17. März 2025, 07:03 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca: Acquisition Expected to Close in 2Q 2025

17. März 2025, 07:03 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

17. März 2025, 07:01 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca to Make Initial Payment of $425M on Deal Closing

17. März 2025, 07:01 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca Buying EsoBiotec for up to $1B

17. März 2025, 07:01 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

17. März 2025, 07:00 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca to Buy EsoBiotec

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26. Feb. 2025, 14:59 UTC

Market Talk

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

26. Feb. 2025, 08:04 UTC

Market Talk
Ergebnisse

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

20. Feb. 2025, 11:34 UTC

Akquisitionen, Fusionen, Übernahmen

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20. Feb. 2025, 11:34 UTC

Akquisitionen, Fusionen, Übernahmen

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20. Feb. 2025, 11:33 UTC

Akquisitionen, Fusionen, Übernahmen

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20. Feb. 2025, 11:33 UTC

Akquisitionen, Fusionen, Übernahmen

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20. Feb. 2025, 11:31 UTC

Akquisitionen, Fusionen, Übernahmen

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20. Feb. 2025, 11:30 UTC

Akquisitionen, Fusionen, Übernahmen

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

13. Feb. 2025, 10:49 UTC

Market Talk
Ergebnisse

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

7. Feb. 2025, 10:30 UTC

Top News

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6. Feb. 2025, 15:18 UTC

Market Talk

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6. Feb. 2025, 13:24 UTC

Market Talk

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

6. Feb. 2025, 12:01 UTC

Ergebnisse

Global Stocks in Spotlight: BYD, Kering, Maersk -- WSJ

6. Feb. 2025, 11:22 UTC

Market Talk
Ergebnisse

AstraZeneca's Sales Beat, Pipeline Outshines Margin Miss -- Market Talk

Peer-Vergleich

Kursveränderung

AstraZeneca PLC Prognose

Kursziel

By TipRanks

22.93% Vorteil

12-Monats-Prognose

Durchschnitt 13,802.5 GBX  22.93%

Hoch 19,000 GBX

Tief 10,900 GBX

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AstraZeneca PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

14 ratings

10

Buy

4

Halten

0

Sell

Stimmung

By Acuity

156 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.